In 2015, the Food and Drug Administration approved flibanserin (Addyi) as the first treatment for hypoactive sexual desire
disorder in premenopausal women.
These allowed claims under the patent Application Serial Number 14/704,223 cover methods of treating female sexual dysfunction and hypoactive sexual desire
disorder (HSDD) with bremelanotide, an investigational product designed for on-demand treatment of HSDD in premenopausal women.
Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire
Hypoactive sexual desire
disorder (HSDD), a common sexual complaint affecting approximately 1 in 10 women in the USA, Europe and Australia, is a multifactorial and multifaceted disorder with biological, psychological and interpersonal relationships all being potential contributing factors.
After discussion of the nature and causes of these problems, and issues and debates, a group of psychologists, psychiatrists, and sexual medicine specialists from the US and Canada address treatment of hypoactive sexual desire
disorder using a variety of therapies, such as cognitive-behavioral and mindfulness-based therapy, crucible therapy, and pharmacology, as well as the role of androgens, assessment, comorbid individual and relationship dysfunction, sexual desire after breast cancer, and other topics.
Hypoactive Sexual Desire
Disorder: When sexual fantasies or thoughts and desire for sexual activity are persistently reduced or absent causing distress or relationship difficulties, the problem is known as hypoactive sexual desire
disorder, or inhibited sexual desire disorder.
A discussion of sexual dysfunction at this end of the continuum and cases of Hypoactive Sexual Desire
Disorder and Vaginismus demonstrate the clinical effectiveness of an approach combining hypnosis and ego-state therapy to facilitate healthy adaptive differentiation.
for treating women with hypoactive sexual desire
The authors suggest that these improvements are clinically valuable, offering relief for women with hypoactive sexual desire
disorder and low oestrogen levels and adding to the list of pharmacological agents available to help older people to enjoy their sex lives.
Letrozole versus testosterone: a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire
disorder and raised estradiol levels
This tool could be beneficial for use in therapy for women diagnosed with hypoactive sexual desire
disorder, or loss of sexual desire, which is the leading sexual problem among females in the world today.
Acquired type hypoactive sexual desire
and sexual stress in the relationships contributed independently to depression in the study sample.